Canterbury DHB
Most patients with Type I von Willebrand disease can be managed with desmopressin. Desmopressin increases factor VIII levels to a similar or greater extent than in patients with mild haemophilia and shortens or normalises the skin bleeding time and platelet function assay (PFA-100). Some, but not all, Type IIA VWD patients respond to desmopressin. In Type IIB disease desmopressin fails to shorten the bleeding time and may produce a severe transient thrombocytopenia. Desmopressin is contraindicated in Type IIB VWD and pseudo-von Willebrand disease. It is useless in Type III VWD.
See the Desmopressin Data Sheets on Medsafe for dosage, precautions, side effects and contraindications.
Topic Code: 5277